Santen Corporate (EN)

2018 IR News

RSS

IR News

Santen and Ube Industries Announce Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in Japan
Corporate Governance Report
Santen Reports the 2nd Quarter Fiscal 2018 Consolidated Performance
Santen Announces Drug Discovery and Development Agreement with PeptiDream
Santen Donates to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan
Santen Files for Manufacturing and Marketing Approval of Anti-Allergy Ophthalmic Drug Candidate DE-114A (JAN: Epinastine Hydrochloride)
Santen and Ube Industries Announce Receipt of Manufacturing and Marketing Approval for Glaucoma and Ocular Hypertension Treatment EYBELIS in Japan
Personnel Changes of Corporate Officer
Personnel Changes of Representative Director of the Board
Santen Reports the 1st Quarter Fiscal 2018 Consolidated Performance
Notice on Completion of Payment for Issuance of New Shares Under Restricted Stock-linked Remuneration Program
Santen Donates to Japan Flood and Landslide Relief Efforts
Santen Receives Marketing Authorisation from the European Commission for DE-076C (Verkazia) as an Orphan Medicinal Product
Corporate Governance Report
Notice on the Issuance of New Shares Under Restricted Stock-Linked Remuneration Program
Santen Announces Medium-Term Plan (MTP2020)
Notice of Board of Director and Corporate Auditor Nominations
Notice on the Introduction of a New Stock-Linked Remuneration Program and Change to Director Remuneration
Santen Reports Fiscal 2017 Consolidated Performance
Notice of Corporate Officer Appointments
Santen to Conduct a Public Awareness Campaign for Glaucoma During World Glaucoma Week March 11 - 17
Santen Announces Appointment of New President
Santen Reports the 3rd Quarter Fiscal 2017 Consolidated Performance